12:00 AM
 | 
Aug 15, 2011
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Northwest Biotherapeutics sales and marketing update

Northwest said its DCVax immunotherapies would be priced in the range of $37,000 per year for up to three years of treatment. The announcement came in response to investors' concerns over pricing and...

Read the full 141 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >